This year marks my third consecutive year attending this amazing conference of 40,000+ attendees. And every year it has proven to be transformative in terms of science and clinical advances for oncology professionals from around the world there to discuss state-of-the-art treatment modalities, new therapies, and ongoing developments in the field. Having focused much of […]Read Full Article
Welcome to the Blue Fin Group Information Library. Our consultants regularly publish white papers, case studies and articles, lead workshops, deliver speaking engagements, and share opinions on topics of interest to decision makers in the healthcare industry.
You don’t become an industry leader without having alot to say—click on the video vignettes below to hear our expert’s perspectives on a range of topics.
Blue Fin Group is often sought out as an expert commentator by industry publications — featuring our latest thinking and timely insights on the issues that matter most to the healthcare industry.
Blue Fin Group keeps a lens trained on many facets of the healthcare industry, and our white papers focus on singular topics that are relevant and timely. Known for our out-of-the-box thinking, these insights provide a deeper dive or different viewpoint from what others in the industry provide.
Case studies that show the transformation from challenge to solution. Each one details the existing situation, Blue Fin Group’s unique approach, the solution deployed, and the results achieved on behalf of the client. At Blue Fin Group, we deliver Deep Knowledge. Powerful Results.
Deep knowledge, unique insights and powerful perspectives focused on the healthcare industry, provided by Blue Fin Group associates.
It’s such an amazing time to be working in healthcare from a market access, and more broadly, a commercialization perspective. We are seeing more and more innovative and transformative medicines come to market in therapeutic areas where such treatment did not exist before. We are seeing diseases that were once death sentences become chronic diseases […]Read Full Article
The “mega rule” has been officially withdrawn, effective November, 2014. BFG has been on record since May 23, 2014, when the US District Court for DC overturned the 340B Orphan Drug rule, questioning whether HHS really had the authority to issue the 340B “mega rule” with guidance around the following: -Definition of an eligible patient -Compliance […]Read Full Article
CHANGE is here. The disruption couldn’t be any louder and it’s unfolding every day, almost like a storm. Billions of dollars in revenue have disappeared or will disappear for branded manufacturers between 2010 and 2020 as a result of patent expirations. Filling in for the blockbuster oral solids of yesteryear are specialty drugs, expected to […]Read Full Article